Report of Foreign Issuer (6-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

---

 

FORM 6-K

 

---

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

May 29, 2018

 

---

 

Commission File Number: 001 - 38178

 

---

 

Zealand Pharma A/S

(Exact Name of Registrant as Specified in Its Charter)

 

---

 

Smedeland 36
2600 Glostrup (Copenhagen)
Denmark

(Address of principal executive offices)

 

---

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x          Form 40-F o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  o

 

Furnished as Exhibit 99.1 to this Report on Form 6-K is a company announcement of Zealand Pharma A/S or the Company, dated May 28, 2018, announcing the completion of the second and pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia

 

 

 

---

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Zealand Pharma A/S
	By:	/s/ Mats Blom
		Name:	Mats Blom
		Title:	Chief Financial Officer

 

Date: May 29, 2018

 

2

---

 

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		Company announcement dated May 28, 2018

 

3

---